Skip to main content

Table 2 Subgroup analysis based on the type of chemotherapy and the component of dual agents

From: Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review

Subgroup

Reference

pCR

The type of Chemotherapy

21,25,26,27,28

1.56 (1.23,1.97)

 Paclitaxel

21,26,27

1.55 (1.06,2.28)

 FEC

28

1.48 (1.07,2.03)

 Docetaxel

25

1.72 (1.27,2.34)

Component of dual agents

  

 L + T

21,26,27,28

1.52 (1.15,2.01)

 P + T

25

1.72 (1.27,2.34)

  1. Abbreviations: T Trastuzumab, L Lapatinib, P Pertuzumab.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us